Net Income (Loss) Attributable to Parent in USD of Inhibrx, Inc. from Q1 2019 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Inhibrx, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q1 2019 to Q1 2024.
  • Inhibrx, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 31 Mar 2024 was -$78,710,000.000, a 60.9% decline year-over-year.
  • Inhibrx, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 31 Mar 2024 was -$271,155,000.000, a 66.5% decline year-over-year.
  • Inhibrx, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$241,361,000.000, a 66.2% decline from 2022.
  • Inhibrx, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$145,226,000.000, a 77.6% decline from 2021.
  • Inhibrx, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$81,768,000.000, a 7.41% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Inhibrx, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$271,155,000 -$78,710,000 -$29,794,000 -60.9% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2024
Q4 2023 -$241,361,000 -$93,604,000 -$52,689,000 -1.3% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2024
Q3 2023 -$188,672,000 -$51,789,000 -$16,464,000 -46.6% 01 Jul 2023 30 Sep 2023 10-Q 09 Nov 2023
Q2 2023 -$172,208,000 -$47,052,000 -$9,320,000 -24.7% 01 Apr 2023 30 Jun 2023 10-Q 09 Nov 2023
Q1 2023 -$162,888,000 -$48,916,000 -$17,662,000 -56.5% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024
Q4 2022 -$145,226,000 -$40,915,000 -$19,726,000 -93.1% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2024
Q3 2022 -$125,500,000 -$35,325,000 -$14,745,000 -71.6% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 -$110,755,000 -$37,732,000 -$17,022,000 -82.2% 01 Apr 2022 30 Jun 2022 10-Q 09 Nov 2023
Q1 2022 -$93,733,000 -$31,254,000 -$11,965,000 -62% 01 Jan 2022 31 Mar 2022 10-Q 09 Nov 2023
Q4 2021 -$81,768,000 -$21,189,000 -$3,540,000 -20.1% 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2023
Q3 2021 -$78,228,000 -$20,580,000 -$83,000 -0.4% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022
Q2 2021 -$78,145,000 -$20,710,000 -$2,825,000 -15.8% 01 Apr 2021 30 Jun 2021 10-Q 07 Nov 2022
Q1 2021 -$75,320,000 -$19,289,000 +$804,000 +4% 01 Jan 2021 31 Mar 2021 10-Q 07 Nov 2022
Q4 2020 -$76,124,000 -$17,649,000 -$1,344,000 -8.2% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2022
Q3 2020 -$74,780,000 -$20,497,000 -$334,000 -1.7% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021
Q2 2020 -$74,446,000 -$17,885,000 -$6,800,000 -61.3% 01 Apr 2020 30 Jun 2020 10-Q 09 Nov 2021
Q1 2020 -$67,646,000 -$20,093,000 -$16,246,000 -4.2% 01 Jan 2020 31 Mar 2020 10-Q 09 Nov 2021
Q4 2019 -$51,400,000 -$16,305,000 01 Oct 2019 31 Dec 2019 10-K 12 Mar 2021
Q3 2019 -$20,163,000 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020
Q2 2019 -$11,085,000 01 Apr 2019 30 Jun 2019 10-Q 13 Nov 2020
Q1 2019 -$3,847,000 01 Jan 2019 31 Mar 2019 10-Q 13 Nov 2020

Inhibrx, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$241,361,000 -$96,135,000 -66.2% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2024
2022 -$145,226,000 -$63,458,000 -77.6% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2024
2021 -$81,768,000 -$5,644,000 -7.4% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2023
2020 -$76,124,000 -$24,724,000 -48.1% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2022
2019 -$51,400,000 01 Jan 2019 31 Dec 2019 10-K 12 Mar 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.